Ayvakit (avapritinib) — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient has platelet count ≥ 50 × 10^9/L (≥ 50,000/mcL)
• EITHER patient has indolent systemic mastocytosis OR patient has ONE of the following subtypes of advanced systemic mastocytosis: aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, or mast cell leukemia

Approval duration

1 year